OraSure Technologies (NASDAQ:OSUR) Downgraded to “Hold” Rating by StockNews.com

StockNews.com cut shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a report released on Tuesday morning.

OraSure Technologies Stock Performance

Shares of OraSure Technologies stock opened at $3.90 on Tuesday. The firm has a 50-day moving average of $3.80 and a 200-day moving average of $4.08. OraSure Technologies has a 52-week low of $3.52 and a 52-week high of $8.04. The stock has a market cap of $290.83 million, a PE ratio of 25.99 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The business’s revenue for the quarter was down 55.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.27 EPS. Equities research analysts predict that OraSure Technologies will post -0.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of OSUR. Sei Investments Co. grew its stake in OraSure Technologies by 76.9% during the second quarter. Sei Investments Co. now owns 302,043 shares of the medical instruments supplier’s stock worth $1,287,000 after buying an additional 131,295 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of OraSure Technologies during the 2nd quarter worth approximately $203,000. Cubist Systematic Strategies LLC boosted its position in shares of OraSure Technologies by 573.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 206,612 shares of the medical instruments supplier’s stock worth $880,000 after acquiring an additional 175,937 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of OraSure Technologies by 1,348.5% during the 2nd quarter. Squarepoint Ops LLC now owns 249,641 shares of the medical instruments supplier’s stock worth $1,063,000 after acquiring an additional 232,407 shares in the last quarter. Finally, AXA S.A. increased its stake in OraSure Technologies by 2.5% in the second quarter. AXA S.A. now owns 161,614 shares of the medical instruments supplier’s stock valued at $688,000 after acquiring an additional 3,997 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.